PAD

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
Tuesday, March 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Hyphens Pharma licenses Wynzora® Cream for ASEAN countries from MC2 Therapeutics

Retrieved on: 
Tuesday, March 12, 2024
Cream, TNF, EUR, Psoriasis, Agreement, Inflammation, Patient, PAD, Dermatology, MC2, Skin, Gold, Comorbidity, Safety, Good, Pharmaceutical industry

SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.

Key Points: 
  • SINGAPORE, March 12, 2024 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that its subsidiary, Hyphens Pharma Pte.
  • Ltd., has entered into an exclusive license, supply and commercialisation agreement (the "Agreement") with MC2 Therapeutics ("MC2") for the exclusive rights to register and commercialise Wynzora® Cream and all future product extensions and/or improvements for the topical treatment of plaque psoriasis in the 10 ASEAN countries.
  • Wynzora® Cream ( www.wynzora.com ), is a leading topical treatment for plaque psoriasis, including scalp psoriasis in adults.
  • "Hyphens Pharma is a leading specialty pharma company focused on the commercialisation of innovative pharmaceutical products in the ASEAN region.

Endologix Initiates Percutaneous Transmural Arterial Bypass (PTAB)1 Post-Market Study

Retrieved on: 
Thursday, February 29, 2024
Health, Surgery, Cardiology, Medical Devices, SVS, Woman, TASC, PAD, Moyamoya disease, Society, Vascular disease, SFA, PTAB, Patient, Pharmaceutical industry

The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).

Key Points: 
  • The study will leverage the Vascular Quality Initiative (VQI) registry infrastructure developed and supported by the Society for Vascular Surgery Patient Safety Organization (SVS PSO).
  • The PTAB1 Post-Market Study evaluates the DETOUR System's performance in patients with very long (TASC D) SFA lesions.
  • The study plans to enroll up to 450 subjects, with a focus on including at least 200 women and also features an imaging sub study.
  • “The initiation of the PTAB1 Post-Market Study represents a pivotal moment in our ongoing commitment to advance the treatment of complex peripheral arterial disease.

Cagent Vascular Raises $30 Million Series C Financing

Retrieved on: 
Tuesday, February 20, 2024
Health, FDA, Medical Devices, Hospitals, Surgery, General Health, Cardiology, U.S. Venture Partners, General partnership, Physician, PAD, Silicon, USVP, Patient, Pharmaceutical industry

Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M.

Key Points: 
  • Cagent Vascular, Inc., a rapidly growing commercial stage medical device company, today announced a Series C Financing close in excess of $30M.
  • Participation included new investor Blue Ridge Medical, LLC and existing investors, including Sectoral Asset Management.
  • “We are pleased with the significant investment from U.S. Venture Partners and other new and existing investors.
  • This was further underscored by the strong early commercial success driven by the exceptional team at Cagent Vascular,” said Casey Tansey, General Partner, US Venture Partners.

Zylox-Tonbridge and Avinger Forge Strategic Partnership to Expand Disruptive OCT Solutions for Peripheral Vascular Interventions

Retrieved on: 
Thursday, March 7, 2024
Lightbox, Total, OCT, Physician, Technology transfer, Growth, PAD, Atherectomy, Vascular disease, Patient, Ocelot, Diagnosis, Research, Partnership, Pharmaceutical industry

This collaboration also provides Avinger the opportunity to distribute high-quality peripheral vascular products developed by Zylox-Tonbridge in the United States and Germany.

Key Points: 
  • This collaboration also provides Avinger the opportunity to distribute high-quality peripheral vascular products developed by Zylox-Tonbridge in the United States and Germany.
  • Avinger is globally recognized for its pioneering OCT-guided, catheter-based system and devices, offering real-time intra-vascular imaging during treatment.
  • By collaborating with Avinger, Zylox-Tonbridge is introducing the globally leading OCT-guided vascular treatment technology to the Chinese peripheral intervention market.
  • We believe this collaboration will expand the company's Peripheral Vascular Intervention product portfolio, reinforcing our market leadership, and accelerating the growth of the vessel preparation business in China's peripheral vascular intervention market.

Sensome Announces Initiation of Clinical Trial Assessing Its Tissue Microsensor Technology in Peripheral Artery Disease

Retrieved on: 
Monday, February 12, 2024
Other Health, Research, Radiology, Medical Devices, Clinical Trials, Science, Surgery, Cardiology, FDA, Other Science, Health, Diabetes, Physician, Clinical trial, Hospital, PAD, Patient, Trial of the century, Peripheral artery disease, Stroke, Medical imaging

Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD).

Key Points: 
  • Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD).
  • Clotild® was designated a breakthrough medical device for use in brain arteries by the FDA in 2021.
  • The clinical trial, named SEPARATE, is designed to assess the Clotild® sensor's capability to detect various characteristics of blood vessel blockages in PAD patients.
  • A key focus of the SEPARATE clinical trial is to evaluate the Clotild® sensor's capacity in differentiating between soft and friable "fresh" clots and organized "old" clots.

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

Retrieved on: 
Monday, February 12, 2024
Essential medicines, CE, Rivaroxaban, VTE, Anticoagulant, INR, Roche, Edoxaban, Direct factor Xa inhibitors, PAD, Stroke, Moyamoya disease, Risk, CAD, Ventricular fibrillation, Health, Patient, Labs, Coronary thrombosis, Diagnosis, Laboratory, Coronary artery disease

"Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.

Key Points: 
  • "Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.
  • "These numbers and our growing understanding of these diseases are leading to a sharp rise in global demand for direct oral anticoagulants.
  • We want to help labs meet this increased need for testing to better inform patient care.
  • These tests can be used for both assessing the anti-Xa activity of heparin therapy as well as the three authorised Factor Xa inhibitors.

NEW DATA: 70% OF AMERICANS UNAWARE OF COMMON VASCULAR DISEASE THAT IS ONE OF THE LEADING CAUSES OF AMPUTATION

Retrieved on: 
Thursday, February 8, 2024
Pulse, Interventional radiology, Health equity, SCAI, Society for Vascular Surgery, Pain, Peripheral artery disease, MD Anderson Cancer Center, Prevalence, Interventions, SIR, University, Heart, Health, Amputation, Society, Diabetes, Heated tobacco product, Smoker, Risk, Patient, Leg, Rest, Vascular disease, Society of Interventional Radiology, PAD, Walking, MBA, Association of Black Cardiologists, Doctor of Philosophy

WASHINGTON, Feb. 8, 2024 /PRNewswire/ -- According to a new national survey released today by the PAD Pulse Alliance, 70% of Americans are unaware of peripheral artery disease (PAD) – the most common vascular disease in which leg arteries become narrowed, reducing or cutting off blood flow, contributing to 400 amputations performed each day in the United States. The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities. Yet among Black and Hispanic adults, nearly 80% report never having a doctor or healthcare provider discuss PAD with them – underscoring the need to start the conversation.

Key Points: 
  • The top risk factors for PAD are common chronic health conditions that disproportionately impact underserved communities.
  • That's why we're encouraging anyone with leading risk factors, diabetes, high blood pressure and use of tobacco products, to know your 'three for PAD' and talk to your doctor."
  • Data from the PAD Pulse Alliance survey highlights a disconnect among people between the risk factors and their personal perceived risk of PAD.
  • Nearly eight in 10 Black and Hispanic never had a doctor or healthcare provider talk with them about PAD.

CyberLink’s Facial Recognition Engine, FaceMe®, Powers 2-Factor Biometric Authentication Solution for South Korean Banking Sector

Retrieved on: 
Tuesday, January 30, 2024
Software, Finance, Artificial Intelligence, Banking, Professional Services, Technology, Other Technology, Security, PAD, AI, Single sign-on, CyberLink, Government, Security agency, KISA, SDK, SSO, FATE, Information, NIST, Risk, HR, Insurance, Facial recognition, Organization, Online shopping

Leading AI facial recognition provider, CyberLink Corp. (5203.TW), today announces a new collaboration with South Korean company, UNIONCOMMUNITY.

Key Points: 
  • Leading AI facial recognition provider, CyberLink Corp. (5203.TW), today announces a new collaboration with South Korean company, UNIONCOMMUNITY.
  • In addition to the existing FaceMe® SDK integration into their UBio-X Face Premium terminal for access control, CyberLink's globally renowned FaceMe® facial recognition technology is now integrated into UNIONCOMMUNITY's latest server-based authentication solution, Ubio-ezPass.
  • Currently, Ubio-ezPass is successfully implemented into a major South Korean financial institution and is expanding to other insurance and securities companies that require two-factor authentication for identity verification.
  • Ubio-ezPass utilizes the highly accurate FaceMe® facial recognition engine to provide two-factor authentication, enhancing user identification.

Reviewers Bestow a Literary Global Gold Award 2023 on Dr. Zekeh Gbotokuma's Book, OBAMANOMICS AND FRANCISCONOMICS

Retrieved on: 
Wednesday, January 31, 2024
Multimedia, PAD, African, Jury, Climate change, Democracy, JEAN, Publication, Morgan State University, Diversity, Philosophy, LGBA, Name, Certificate, Poverty, Economics, Catholic Church, Associate, Green, Social change, Gold

BALTIMORE, Jan. 31, 2024 /PRNewswire/ -- OBAMANOMICS AND FRANCISCONOMICS won the LITERARY GLOBAL BOOK AWARDS (LGBA) 2023 in the category of Social Change.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 /PRNewswire/ -- OBAMANOMICS AND FRANCISCONOMICS won the LITERARY GLOBAL BOOK AWARDS (LGBA) 2023 in the category of Social Change.
  • In the December 20, 2023, email announcement with the subject line, "** LGBA WINNER**," LITERARY GLOBAL wrote, inter alia,
    "Congratulations on your book being awarded a category prize in the inaugural Literary Global Book Awards!
  • It confirms Pegasus International's Literary Awards bestowed on the book in Milan (2022) and Cattolica, Italy (2023).
  • Mudimbe's words, Gbotokuma is delighted to receive literary prizes that contain the terms 'International' and 'Global' in their names.